UC Berkeley’s cancer therapy developer priced a $304m initial public offering at the top of its range.
Caribou Biosciences, a US-based cell therapy developer spun out of University of California, Berkeley is going public today in a $304m initial public offering.
The company increased the number of shares in the offering from 17 million to 19 million and priced them at the top of the IPO’s $14 to $16 range. It is floating on the Nasdaq Global Select Market and the share price gives it a valuation of almost $910m.
Caribou is leveraging its…
